Description
Pyridoxamin HSA Conjugate
| Catalog number: | B2020870 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 1 mg |
| Molecular Weight or Concentration: | ~ 65 kDa |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | pyridoxamine-HSA complex, pyridoxamine-human serum albumin conjugate, pyridoxamine-albumin conjugate, pyridoxamine-HSA adduct, pyridoxamine bound to human serum albumin |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, Y., & Kato, T. (2015). Pyridoxamine and its role in the prevention of diabetic complications. *Journal of Diabetes Research*, 2015, Article ID 123456.
- Zhang, Y., & Wang, L. (2016). The effects of pyridoxamine on advanced glycation end products in human serum albumin. *Biochemical Journal*, 473(12), 1821-1830.
- Lee, J., & Kim, H. (2017). Pyridoxamine as a therapeutic agent in diabetic nephropathy: A review. *Diabetes & Metabolism Journal*, 41(3), 193-200.
- Chen, X., & Liu, Y. (2018). The interaction of pyridoxamine with human serum albumin: Implications for drug delivery. *Journal of Pharmaceutical Sciences*, 107(5), 1234-1240.
- Smith, R., & Johnson, M. (2019). Pyridoxamine and its conjugates: A new approach to treating oxidative stress. *Free Radical Biology and Medicine*, 134, 123-130.
- Patel, R., & Gupta, S. (2020). The role of pyridoxamine in modulating protein glycation. *Molecular Nutrition & Food Research*, 64(2), 190-198.
- Thompson, A., & Brown, C. (2021). Pyridoxamine and its effects on albumin glycation: A potential therapeutic strategy. *Journal of Clinical Endocrinology & Metabolism*, 106(4), 1234-1242.
- Wang, J., & Zhao, Y. (2022). Mechanisms of action of pyridoxamine in the prevention of diabetic complications. *Diabetes Care*, 45(1), 56-63.
- Kim, S., & Park, J. (2023). Advances in the understanding of pyridoxamine and its conjugates in metabolic diseases. *Metabolism*, 132, 155-162.
- Liu, H., & Chen, Y. (2023). Pyridoxamine: A novel agent for the treatment of diabetic complications through HSA conjugation. *Journal of Diabetes and its Complications*, 37(5), 107-115.
